SIGA Technologies

$13.68 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security market. The Company’s lead product TPOXX is approved by the Unites States Food and Drug Administration (FDA) as a drug with an indication for treatment of smallpox. TPOXX is an oral formulation, which is also known as tecovirimat and ST-246. The Company is developing the intravenous (IV) formulation for patients who are unable to swallow oral capsules. It is also focused on developing post-exposure prophylaxis (PEP), liquid suspension pediatric formulation and ST-357. PEP regimens are designed to prevent infection in individuals who have known or exposure to an infectious agent but are not symptomatic. The Company is developing a second mechanism of action smallpox small molecule antiviral drug that has shown efficacy in animal models of the disease.

Stock Analysis

last close $13.68
1-mo return 106%
3-mo return 122.8%
avg daily vol. 16.94M
52-week high 14.8
52-week low 5.66
market cap. $898M
forward pe 20.7
annual div. -
roe 48.1%
ltg forecast -
dividend yield -
annual rev. $139M
inst own. 37.8%

Subscribe now for daily local and international financial news